{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-023899","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.585898+00:00","generated_at":"2026-06-15T06:05:21.543343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADMA Biologics Q1 revenue $56.9M (+96% YoY); first-time positive Adjusted EBITDA $2.5M","bullets":["Total revenues $56.9M, up 96% YoY; net loss narrowed to $6.8M from $25.0M.","First-time positive Adjusted EBITDA of $2.5M, ahead of forecast; FY2023 revenue guidance raised to >$220M.","Gross margin improved to 29.0% from 12.6%; legacy low-margin BIVIGAM inventory nearly depleted.","ASCENIV production scaled to 4,400L; expects margin expansion and plant capacity improvement.","Cash $69.2M; working capital $227.4M; strategic review ongoing with Morgan Stanley."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-023899","json":"https://secwatch.observer/filing/0001140361-23-023899.json","markdown":"https://secwatch.observer/filing/0001140361-23-023899.md","text":"https://secwatch.observer/filing/0001140361-23-023899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/brhc20052575_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:05:21.543343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dfeec37ca1b69a2f27c82363406db0737c87f97","claim":"ADMA BIOLOGICS, INC. reported first quarter 2023 results: revenue $57 Million, net income Net Loss of $6.8 Million.","evidence_excerpt":"1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$57 Million"},{"label":"Net income","value":"Net Loss of $6.8 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"af872cdb0b68e84b89cad9de6078c3f5de19b923","claim":"ADMA BIOLOGICS, INC. reported FY2023 results: revenue $220 Million. Guidance raised.","evidence_excerpt":"FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from $210 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023"},{"label":"Revenue","value":"$220 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}